Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019)

Lineage Cell Therapeutics' Long-Term Investments history runs 4 years deep, the most recent figure standing at $19.0 million for Q4 2019.

• On a quarterly basis, Long-Term Investments rose 40.92% year-over-year to $19.0 million in Q4 2019; TTM through Dec 2019 was $19.0 million, a 40.92% increase from a year earlier, with the FY2019 full-year figure at $19.0 million, up 40.92% from the prior year.
• Long-Term Investments advanced to $19.0 million in Q4 2019 per LCTX's latest filing, from $17.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $110.8 million in Q3 2017 and bottomed at $3.5 million in Q3 2016.
• The 4-year median for Long-Term Investments is $33.7 million (2018), against an average of $45.2 million.
• Across the five-year window, Long-Term Investments soared 3082.08% in 2017 and slumped 80.23% in 2018, its largest moves.
• Year by year, Long-Term Investments stood at $100.0 million in 2016, then slumped by 31.8% to $68.2 million in 2017, then slumped by 80.23% to $13.5 million in 2018, then surged by 40.92% to $19.0 million in 2019.
• Per Business Quant, the three latest LCTX Long-Term Investments figures stand at $19.0 million (Q4 2019), $17.7 million (Q3 2019), and $36.5 million (Q2 2019).